Bandwidth (NASDAQ:BAND – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at William ...

William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

William Blair downgraded Booz Allen (BAH) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: See what ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

William Blair analyst Arjun Bhatia maintained a Buy rating on Radcom (RDCM – Research Report) today. The company’s shares opened today at ...

William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named managing directors John Ivey and B.T. Remmert as the ...

Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago ...

Pediatrix Medical reported Q4 revenue of $502.36 million, surpassing estimates, with adjusted EPS of $0.51. The company ...

The Fund seeks long-term capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of equity securities, including common ...